Sculptra.com: For Healthcare Professionals

FOR U.S. RESIDENTS ONLY

	How Sculptra® Works
	Volumetric Improvement
	Safety and Tolerability
	Find a Sales Consultant
	Order Sculptra®
	Product Information

Enter your zip code to search for a healthcare provider near you.


Search by street address

Site (keyword)

Providers (zip code)

The Art and Science of Sculptra™

Sculptra® is intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus.¹

VOLUME	DURATION	SAFETY
Restores fullness of the face,^3,4 creating a more natural appearance	Improvements in dermal thickness lasted for up to 2 years¹	Clinically proven safe and well tolerated No skin test required Biodegradable, biocompatible¹

Eligibility for training
Dermik provides training to physicians who treat patients for the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus. Currently, training is offered to board-certified plastic surgeons, board-certified facial plastic surgeons, board-certified dermatologists, and HIV specialists. For more information about training, please contact a Sculptra® sales consultant.

Please note: If your specialty is not among those listed above as eligible for training, we cannot guarantee that a Sculptra® sales consultant will reply to your request at this time.

	Learn more about Sculptra® and find out if it's right for your practice.
	-	How Sculptra® Works
	-	Volumetric Improvement
	-	Safety and Tolerability
	-	FAQ
	-	The History of Sculptra®
	-	Product Information
	For more information, or to report an adverse event, please contact us.

	-	Find a Sales Consultant
	-	Order Sculptra® for Your Practice
	-	Get Listed in Our Healthcare Provider Locator

Characteristics and Progression

Sculptra® is injected into the skin for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus.

IMPORTANT SAFETY INFORMATION

Sculptra® is contraindicated in those individuals who have shown a hypersensitivity to any of its components. Sculptra® should not be injected in areas with active skin infection or inflammation. Avoid injection into the blood vessels.

The most commonly observed adverse event was the delayed occurrence of subcutaneous papules, which were confined to the injection site and were typically palpable, asymptomatic, and non-visible. Visible nodules, with or without inflammation or dyspigmentation, have also been reported. Other adverse events include immediate and transient injection-related events such as bleeding from the injection site, discomfort, erythema or inflammation, ecchymosis, and edema.

For more information, please see Full Product Information for Sculptra®